title: Targeting a common collaborator in cancer development.
abstract: In this issue of Science Translational Medicine, Wallin et al. have identified a subset of breast and ovarian cancer cell lines that show synergistic response to the combination of doxorubicin and GDC-0941, a class IA phosphatidylinositol 3-kinase (PI3K) inhibitor. Here, we discuss the potential implications of these data on the clinical development of PI3K pathway inhibitors as cancer therapeutics.
authors.affiliation: Division of Women's Cancers, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA. apmyers@partners.org
authors.forename: Andrea P
authors.initials: AP
authors.lastname: Myers
authors.forename: Lewis C
authors.initials: LC
authors.lastname: Cantley
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000494:pharmacology* / Q000627:therapeutic use; D014408:Biomarkers, Tumor; D045744:Cell Line, Tumor / Q000187:drug effects*; D004317:Doxorubicin / Q000494:pharmacology* / Q000627:therapeutic use; D004357:Drug Synergism; D006801:Humans; D007191:Indazoles / Q000494:pharmacology* / Q000627:therapeutic use; D009369:Neoplasms / Q000188:drug therapy / Q000503:physiopathology*; D000081082:Phosphoinositide-3 Kinase Inhibitors; D013449:Sulfonamides / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: C532162:2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine; D000903:Antibiotics, Antineoplastic; D014408:Biomarkers, Tumor; D007191:Indazoles; D000081082:Phosphoinositide-3 Kinase Inhibitors; D013449:Sulfonamides; D004317:Doxorubicin
references.citation: Science. 1987 Jan 9;235(4785):177-82
references.pmid: 3798106
references.citation: Oncogene. 2008 Sep 18;27(41):5497-510
references.pmid: 18794884
references.citation: Clin Breast Cancer. 2005 Aug;6(3):240-6
references.pmid: 16137435
references.citation: Cancer Biol Ther. 2006 Jul;5(7):779-85
references.pmid: 16721043
references.citation: J Clin Oncol. 2012 Jan 20;30(3):282-90
references.pmid: 22162589
references.citation: PLoS One. 2008 Aug 26;3(8):e3065
references.pmid: 18725974
references.citation: Nat Med. 2008 Dec;14(12):1351-6
references.pmid: 19029981
references.citation: Oncogene. 2008 Sep 18;27(41):5527-41
references.pmid: 18794886
references.citation: Cancer Res. 2001 Aug 15;61(16):5985-91
references.pmid: 11507039
references.citation: Nat Rev Genet. 2006 Aug;7(8):606-19
references.pmid: 16847462
references.citation: Curr Protoc Hum Genet. 2008 Apr;Chapter 10:Unit 10.11
references.pmid: 18428421
references.citation: J Clin Oncol. 1996 Mar;14(3):737-44
references.pmid: 8622019
references.citation: Nat Rev Cancer. 2009 Aug;9(8):550-62
references.pmid: 19629070
references.citation: Oncologist. 2006 Jun;11(6):541-52
references.pmid: 16794234
references.citation: Cancer Cell. 2009 Aug 4;16(2):115-25
references.pmid: 19647222
references.citation: Science. 1997 Mar 28;275(5308):1943-7
references.pmid: 9072974
references.citation: Cancer Res. 2004 Nov 1;64(21):7678-81
references.pmid: 15520168
references.citation: CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
references.pmid: 19474385
references.citation: J Clin Invest. 2008 Sep;118(9):3065-74
references.pmid: 18725988
references.citation: J Clin Oncol. 2010 Feb 20;28(6):1075-83
references.pmid: 20085938
references.citation: Sci Transl Med. 2010 Sep 8;2(48):48ra66
references.pmid: 20826841
references.citation: J Clin Oncol. 1998 Aug;16(8):2659-71
references.pmid: 9704716
references.citation: Science. 2004 Apr 23;304(5670):554
references.pmid: 15016963